Background/Aims: While probiotic bacteria are successfully used in the treatment of ulcerative colitis, the effect of commercially available probiotic products is still controversial. Here, we study whether the number of living probiotic bacteria in yoghurts is altered by an interruption of the cold chain. Methods: Three commonly available probiotic yoghurts were kept at 4°C or put at room temperature (RT) for 6 h or 24 h. An aliquot of each yoghurt was applied on Man-Rogosa-Sharpe agar and incubated at 37°C for 48 h. Colony forming units (CFU) were counted by microscopy. Results: The first yoghurt, containing Lactobacillus johnsonii, showed a significant decrease in CFU after 6 h of storage at RT, which was further pronounced after 24 h. The number of CFU of the second yoghurt, containing Lactobacillus GG, was also decreased after 6 h and further diminished after 24 h at RT. From the third yoghurt, containing Lactobacillus acidophilus, only 53.8% of the CFU remained after 6 h at RT; after 24 h, only about one fourth of the CFU were found. Conclusions: Our data demonstrate that the number of living probiotic bacteria in yoghurt products decreases dramatically after exposure to RT. This represents an important information for consumers of such products.

Journal Section:
Original Paper
Keywords:
Probiotic bacteria, Ulcerative colitis, Probiotic yoghurts, Lactobacillae
1.
Guarner F, Malagelada JR: Gut flora in health and disease. Lancet 2003;361:512–519.
[PubMed]
https://doi.org/10.1016%2FS0140-6736%2803%2912489-0
2.
Beaugerie L, Flahault A, Barbut F, Atlan P, Lalande V, Cousin P, Cadilhac M, Petit JC, Study Group: Antibiotic-associated diarrhoea and Clostridium difficile in the community. Aliment Pharmacol Ther 2003;17:905–912.
[PubMed]
https://doi.org/10.1046%2Fj.1365-2036.2003.01531.x
3.
Kruis W, Schütz E, Fric P, Fixa B, Judmaier G, Stolte M: Double-blind comparison of an oral Eschericia coli preparation and mesalazine in maintaining remission of ulcerative colitis. Aliment Pharmacol Ther 1997;11:853–858.
[PubMed]
https://doi.org/10.1046%2Fj.1365-2036.1997.00225.x
4.
Rembacken BJ, Snelling AM, Hawkey PM, Chalmers DM, Axon AT: Non-pathogenic Eschericia coli versus mesalazine for the treatment of ulcerative colitis: a randomised trial. Lancet 1999;354:635–639.
[PubMed]
https://doi.org/10.1016%2FS0140-6736%2898%2906343-0
5.
Bibiloni R, Fedorak RN, Tannock GW, Madsen KL, Gionchetti P, Campieri M, De Simone C, Sartor RB: VSL#3 probiotic-mixture induces remission in patients with active ulcerative colitis. Am J Gastroenterol 2005;100:1539–1546.
[PubMed]
https://doi.org/10.1111%2Fj.1572-0241.2005.41794.x
6.
Möndel M, Schroeder BO, Zimmermann K, Huber H, Nuding S, Beisner J, Fellermann K, Stange EF, Wehkamp J: Probiotic E. coli treatment mediates antimicrobial human beta-defensin synthesis and fecal excretion in humans. Mucosal Immunol 2009;2:166–172.
https://doi.org/10.1038%2Fmi.2008.77
7.
Wehkamp J, Harder J, Wehkamp K, Wehkamp-von Meissner B, Schlee M, Enders C, Sonnenborn U, Nuding S, Bengmark S, Fellermann K, Schröder JM, Stange EF: NF-kappaB- and AP-1-mediated induction of human beta defensin-2 in intestinal epithelial cells by Eschericia coli Nissle 1917: a novel effect of a probiotic bacterium. Infect Immun 2004;72:5750–5758.
[PubMed]
https://doi.org/10.1128%2FIAI.72.10.5750-5758.2004
8.
Mastrangeli G, Corinti S, Butteroni C, Afferni C, Bonura A, Boirivant M, Colombo P, Di Felice G: Effects of live and inactivated VSL#3 probiotic preparations in the modulation of in vitro and in vivo allergen-induced Th2 responses. Int Arch Allergy Immunol 2009;150:133–143.
[PubMed]
https://doi.org/10.1159%2F000218116
9.
Ukena SN, Singh A, Dringenberg U, Engelhardt R, Seidler U, Hansen W, Bleich A, Bruder D, Franzke A, Rogler G, Suerbaum S, Buer J, Gunzer F, Westendorf AM: Probiotic Eschericia coli Nissle 1917 inhibits leaky gut by enhancing mucosal integrity. PLoS One 2007;2:e1308.
[PubMed]
https://doi.org/10.1371%2Fjournal.pone.0001308
10.
Rasche C, Wolfram C, Wahls M, Worm M: Differential immunomodulating effects of inactivated probiotic bacteria on the allergic immune response. Acta Derm Venereol 2007;87:305–311.
[PubMed]
https://doi.org/10.2340%2F00015555-0232
11.
Schillinger U: Isolation and identification of lactobacilli from novel-type probiotic and mild yoghurts and their stability during refrigerated storage. Int J Food Microbiol 1999;47:79–87.
[PubMed]
https://doi.org/10.1016%2FS0168-1605%2899%2900014-8
© 2010 S. Karger AG, Basel
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
2010
You do not currently have access to this content.